277 related articles for article (PubMed ID: 34972978)
1. Neurologic Toxicities of Immunotherapy.
Harrison RA; Majd NK; Tummala S; de Groot JF
Adv Exp Med Biol; 2021; 1342():417-429. PubMed ID: 34972978
[TBL] [Abstract][Full Text] [Related]
2. Neurological toxicities associated with immune-checkpoint inhibitors.
Touat M; Talmasov D; Ricard D; Psimaras D
Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
[TBL] [Abstract][Full Text] [Related]
3. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department.
Lipe DN; Shafer S
Clin Toxicol (Phila); 2021 May; 59(5):376-385. PubMed ID: 33576256
[TBL] [Abstract][Full Text] [Related]
4. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
Perrinjaquet C; Desbaillets N; Hottinger AF
Curr Opin Neurol; 2019 Jun; 32(3):500-510. PubMed ID: 30893101
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
6. Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents.
Bompaire F; Birzu C; Bihan K; Desestret V; Fargeot G; Farina A; Joubert B; Leclercq D; Nichelli L; Picca A; Tafani C; Weiss N; Psimaras D; Ricard D
Rev Neurol (Paris); 2023 Jun; 179(5):405-416. PubMed ID: 37059646
[TBL] [Abstract][Full Text] [Related]
7. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
8. Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management.
Kovac MB; Seruga B
Radiol Oncol; 2024 Jun; 58(2):170-178. PubMed ID: 38613842
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system injury from novel cancer immunotherapies.
Winter SF; Vaios EJ; Dietrich J
Curr Opin Neurol; 2020 Dec; 33(6):723-735. PubMed ID: 32941192
[TBL] [Abstract][Full Text] [Related]
10. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
Farina A; Villagrán-García M; Honnorat J
Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
[TBL] [Abstract][Full Text] [Related]
11. Neurologic complications of immune checkpoint inhibitors.
Haugh AM; Probasco JC; Johnson DB
Expert Opin Drug Saf; 2020 Apr; 19(4):479-488. PubMed ID: 32126176
[No Abstract] [Full Text] [Related]
12. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y
J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490
[TBL] [Abstract][Full Text] [Related]
13. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
14. The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
Ertl C; Ruf T; Mentzer D; Kong M; Kramer R; Bergwelt-Baildon MV; Subklewe M; Tomsitz D; Ascierto PA; Dummer R; Gogas H; Lebbé C; Long GV; McArthur G; Neilan TG; Ribas A; Robert C; Schadendorf D; Zimmer L; Eigentler T; Grabbe S; Forschner A; Kähler KC; Milani V; Pföhler C; Hassel J; Gutzmer R; Loquai C; Routy B; Furness AJS; Blank C; Wolchok JD; French LE; Hauschild A; Heinzerling L
Eur J Cancer; 2024 Mar; 199():113505. PubMed ID: 38262306
[TBL] [Abstract][Full Text] [Related]
15. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
16. Neurological updates: neurological complications of CAR-T therapy.
Tallantyre EC; Evans NA; Parry-Jones J; Morgan MPG; Jones CH; Ingram W
J Neurol; 2021 Apr; 268(4):1544-1554. PubMed ID: 33140239
[TBL] [Abstract][Full Text] [Related]
17. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
18. Neurologic Complications of Cancer Immunotherapy.
Wang N
Continuum (Minneap Minn); 2023 Dec; 29(6):1827-1843. PubMed ID: 38085900
[TBL] [Abstract][Full Text] [Related]
19. A review of cancer immunotherapy toxicity.
Kennedy LB; Salama AKS
CA Cancer J Clin; 2020 Mar; 70(2):86-104. PubMed ID: 31944278
[TBL] [Abstract][Full Text] [Related]
20. A review of neurotoxicities associated with immunotherapy and a framework for evaluation.
Burton LB; Eskian M; Guidon AC; Reynolds KL
Neurooncol Adv; 2021 Nov; 3(Suppl 5):v108-v120. PubMed ID: 34859238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
